Natascha Schweighofer

Natascha Schweighofer

Auto-generated profile, based on publicly available information

Natascha Schweighofer

Division of Endocrinology and Diabetology, Department of Internal Medicine- Medical University of Graz, Graz, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Talanta
Verified
Journal Article
Open access
BLBassam Lajin
Bassam Lajin
NSNatascha Schweighofer
Natascha Schweighofer
WGWalter Goessler
Walter Goessler
Barbara Obermayer-PietschBarbara Obermayer-Pietsch
Barbara Obermayer-Pietsch
The Cytochrome P450 CYP1A2 is a central enzyme in the metabolism of drugs and xenobiotics. The overall activity of this enzyme is influenced by a complex array of biochemical, dietary, and genetic factors. One of the simplest ways to probe the overall output of CYP1A2 is to measure the ratio between the concentration of a precursor and a product of its activity. With the growing interest in the Paraxanthine/Caffeine ratio, the need arises to develop improved analytical methods specifically optimized for the rapid and sensitive determination of paraxanthine and caffeine in biological samples. We report a new optimized method for the determination of caffeine and paraxanthine in various human matrices. The method involved direct determination following protein precipitation based on ultra high performance liquid chromatographic separation with tandem mass spectrometric detection (UHPLC-ESIMS/MS). The method offers an improvement in the detection limit over previously published methods by at least 10-fold (0.1 pg), rapid chromatographic separation (ca. 5 min), the utilization of a green chromatographic solvent (5% v/v ethanol), direct determination with little sample preparation, and the employment of isotopically labeled internal standards and qualifier ions to ensure accuracy. Method validation in urine, saliva, and plasma was performed by spiking at various concentration levels where the recovery and repeatability were within ±15% and ±10%, respectively. The method was applied to investigate the levels of caffeine and paraxanthine in volunteers following controlled caffeine administration and to investigate the inter- and intra-individual variability in the paraxanthine/caffeine ratio in volunteers following an unrestricted caffeine diet. In conclusion, the developed UHPLC-ESIMS/MS method is optimized specifically for the simultaneous determination of the paraxanthine/caffeine ratio in multiple biological matrices, offers several advantages over the current methods, and is well suitable for application in large clinical studies.

1 June 2009 in Bone
Verified
Journal Article
Closed access
PDF file
EWE. Wehr⁎
E. Wehr⁎
Stefan PilzStefan Pilz
Stefan Pilz
NSN. Schweighofer
N. Schweighofer
Anna Lisa GiulianiAnna Lisa Giuliani
Anna Lisa Giuliani
DKDaisy M. Kop Kopera
Daisy M. Kop Kopera
BOB. Obermayer-Pietsch
B. Obermayer-Pietsch

1 April 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
BFBianca Fuchs-Neuhold
Bianca Fuchs-Neuhold
WSWolfgang Staubmann
Wolfgang Staubmann
MPMarie Peterseil
Marie Peterseil
ARAnna Rath
Anna Rath
NSNatascha Schweighofer
Natascha Schweighofer
EPElisabeth Pail
Elisabeth Pail
Background: Early experiences with different flavors play an important role in infant development, including food and taste acceptance. Flavors are already perceived in utero with the development of the taste and olfactory system and are passed on to the child through breast and bottle feeding. Therefore, the first 1000 days of life are considered a critical window for infant developmental programming. Objective: The objective of our study is to investigate, both in the prenatal and postnatal period, taste sensitivity, preferences, and dietary diversity of mother-infant pairs. The explorative study design will also report on the impact of these variables on body composition (BC) and biomarkers. In contrast to conventional methods, this study involves long-term follow-up data collection from mother-infant pairs; moreover, the integration of audiovisual tools for recording infants' expressions pertaining to taste stimuli is a novelty of this study. Considering these new methodological approaches, the study aims to assess taste-related data in conjunction with BC parameters like fat-free mass or fat mass, biomarkers, and nutritional intake in infants and children. Methods: Healthy pregnant women aged between 18 and 50 years (BMI >= 18.5 kg/m(2) to <= 30 kg/m(2); <28 weeks of gestation) were recruited from January 2014 to October 2014. The explorative design implies 2 center visits during pregnancy (24-28 weeks of gestation and 32-34 weeks of gestation) and 2 center visits after delivery (6-8 weeks postpartum and 14-16 weeks postpartum) as well as follow-up visits at 1, 3-3.5, and 6 years after delivery. Data collection encompasses anthropometric and biochemical measurements as well as BC analyses with air displacement plethysmography, taste perception assessments, and multicomponent questionnaires on demographics, feeding practices, and nutritional and lifestyle behaviors. Audiovisual data from infants' reactions to sensory stimuli are collected and coded by trained staff using Baby Facial Action Coding and the Body Action Posture System. Birth outcomes and weight development are obtained from medical records, and additional qualitative data are gathered from 24 semistructured interviews. Results: Our cohort represents a homogenous group of healthy women with stringent exclusion criteria. A total of 54 women met the eligibility criteria, whereas 47 mother-child pairs completed data collection at 4 center visits during and after pregnancy. Follow-up phases, data analyses, and dissemination of the findings are scheduled for the end of 2023. The study was approved by the ethics committee of the Medical University of Graz (EC No 26-066 ex 13/14), and all participants provided informed consent. Conclusions: The results of this study could be useful for elucidating the connections between maternal and infant statuses regarding diet, taste, biomarkers, and prenatal and postnatal weight development. This study may also be relevant to the establishment of further diagnostic and interventional strategies targeting childhood obesity and early body fat development.

15 May 2021 in Endocrine Abstracts
Verified
Journal Article
Closed access
MSMoritz Strasser
Moritz Strasser
NSNatascha Schweighofer
Natascha Schweighofer
AOAnna Obermayer
Anna Obermayer
VBValentin Borzan
Valentin Borzan
CHChristoph Haudum
Christoph Haudum
Barbara Obermayer-PietschBarbara Obermayer-Pietsch
Barbara Obermayer-Pietsch
Background Metformin is a widely used and effective agent in type 2 diabetes mellitus (T2DM) and polycystic ovary syndrome (PCOS). Yet, the mechanisms of action and the occurrence of side effects (e.g. abdominal bloating and pain), are still poorly understood. Since organic cation transporters (OCTs) are responsible for the hepatic and renal transport of metformin, we investigated a series of short nucleotide polymorphisms (SNPs) in the OCT genes in PCOS and in T2DM patient samples from either our PCOS patient registry or the Graz Diabetes Registry for Biomarker Research (GIRO). Methods After DNA isolation from plasma in 181 PCOS samples and 44 T2DM samples followed by a subsequent polymerase chain reaction (PCR) with a combined TaqMan assay, we compared 17 SNPs (rs456598, rs461473, rs3798174, rs7766568, rs316007, rs3798167, rs662301, rs2048327, rs376563, rs622591, rs9295125, rs3798172, rs2197296, rs12208357, rs34059508, rs628031 and rs3777392) from OCT1 and OCT3 transporters. Results Data of the study participants were analyzed according to the presence or absence of documented metformin-induced side effects. The distributions of different genotypes of the rs2197296 locus in the SLC22A1 gene, the rs376563 locus in the SLC22A2 gene and the rs3798167 locus in the SLC22A3 gene were statistically significant between the two groups. The effect was shown by a higher minor allele frequency in the group with documented metformin associated side effects (χ(2) = 3.953, P = 0.047, χ(2) = 7.342, P = 0.025 and χ(2) = 12.251, P = 0.002 respectively). Conclusion In conclusion, we found three specific allelic variants in OCT candidate genes with distinct associations for side effects in metformin users either in PCOS or in T2DM. Therefore, those variants can be further investigated to better understand the metformin-associated side effects.

1 December 2018 in Journal of Laboratory and Precision Medicine
Verified
Journal Article
Open access
Barbara Obermayer-PietschBarbara Obermayer-Pietsch
Barbara Obermayer-Pietsch
VFVito Francic
Vito Francic
CHChristoph Haudum
Christoph Haudum
VBValentin Borzan
Valentin Borzan
NSNatascha Schweighofer
Natascha Schweighofer
IFInes Foessl
Ines Foessl
Osteoporosis and diabetes mellitus type 2 (T2DM) are frequently coinciding in elderly patients, increasing with age. The disease is associated with a higher fracture risk despite normal to high planar bone mineral density (BMD) as measured by dual energy bone densitometry (DXA) in these individuals. As BMD measurements do not identify T2DM patients at risk for bone fractures, this coincidence has not been recognized for a long time, though higher mortality and the risk of a delayed wound healing have been found in T2DM patients with major fractures. In patients with diabetes mellitus type 1 (T1DM) fracture risk is even higher, with an up to 12-fold risk as compared to patients with normal glucose metabolism. These patients might be affected from early childhood on, with worse fracture outcomes depending on their glucose control. Pathophysiological conditions that might contribute to the increased fracture risk in both T1DM and T2DM include decreased skeletal quality and properties, aggravated by comorbidities such as macro- and microvascular complications, and chronic inflammation, but there are many open questions to resolve. As specific diagnostic approaches are urgently required, several attempts have been made by new imaging technologies, namely trabecular bone score (TBS), high resolution peripheral quantitative computed tomography (HRpQCT), bone biopsies, histomorphometry and microindentation. New biomarkers of diabetoporosity have been addressed. The complex interaction of these new biomarkers is illustrated by several articles within this issue. We report on the current knowledge in pathophysiology, diagnostics and management of bone in diabetes mellitus. Given the increasing numbers of T2DM and osteoporosis patients worldwide—with a current number of about 415 million T2DM patients, a growing community of T1DM patients and about 9 million osteoporotic fractures annually in 200 million women and probably 120 million men—this is in fact an important problem for future health care.

15 June 2022 in Bone Reports
Verified
Journal Article
Open access
NSNatascha Schweighofer
Natascha Schweighofer
CCCaterina Colantonio
Caterina Colantonio
CHChristoph Haudum
Christoph Haudum
BHBarbara Hutz
Barbara Hutz
ASAlbrecht Schmidt
Albrecht Schmidt
BOBarbara Obermayer-Pietsch
Barbara Obermayer-Pietsch